

Practice Plus Group Topco Limited

Unaudited financial results for the six months ended 31 March 2024



Group Overview and financial highlights



- The Group has continued to grow its revenue year on year with profitability impacted by cost inflation.
- The table below shows the key performance indicators for the Group's operations for the six months ended 31 March 2024.

H1 FY24 Results	Re
£m	2024
Health in Justice	11
Integrated Urgent Care	6
Secondary Care	11
Central Services & Eliminations	(0
Total Group	29

Revenue		EBITDA 1		
2024		2023	2024	20
11	6.5	98.9	12.3	
6	51.1	59.8	4.3	
11	3.4	103.4	11.6	
(0	0.3)	(0.2)	(3.5)	
29	0.8	261.9	24.7	

2023

10.7 6.1 10.7 (3.1)

- Health in Justice has had contract wins and retentions during H1 with net growth in both revenue and EBITDA.
- Integrated Urgent Care has seen a modest increase in revenue with reduced Winter funding, this combined with higher staff costs have led to a reduction in EBITDA.
- The Secondary Care division continues to see revenue increases as volumes and productivity have improved. EBITDA
 has grown but is still impacted by inflationary cost pressures. The Group has launched a new sub-brand for its self-pay
 surgery options to market directly to consumers. This has been supported by a new advertising campaign across all
 media platforms including television.
- Central Services costs were higher due to additional headcount and project costs.

¹ EBITDA is the Group's key profitability metric, being operating profit/(loss) for the period adjusted for non-recurring items, depreciation, amortisation and impairment.